{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:20:30Z","timestamp":1764087630202,"version":"3.45.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40487-025-00383-x","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:07:35Z","timestamp":1759482455000},"page":"1119-1141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Immuno-oncology-Induced Cytokine Release Syndrome Patient Diary: A Content-Valid, Patient-Reported Outcome Measure"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8255-2801","authenticated-orcid":false,"given":"Edward Ted","family":"Wells","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Lucats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce R.","family":"Talavera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie R.","family":"Van Tomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Arnould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Reaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Coulouvrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"14","key":"383_CR1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.04.01","volume":"4","author":"NE Papaioannou","year":"2016","unstructured":"Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261.","journal-title":"Ann Transl Med"},{"key":"383_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00064","volume":"7","author":"J Kamta","year":"2017","unstructured":"Kamta J, Chaar M, Ande A, Altomare DA, Ait-Oudhia S. Advancing cancer therapy with present and emerging immuno-oncology approaches. Front Oncol. 2017;7:64.","journal-title":"Front Oncol"},{"key":"383_CR3","unstructured":"Institute CR. Regulatory approval timeline of active immunotherapies. 2025 [cited; Available from: https:\/\/www.cancerresearch.org\/regulatory-approval-timeline-of-active-immunotherapies"},{"key":"383_CR4","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","volume":"10","author":"P Dobosz","year":"2019","unstructured":"Dobosz P, Dzieciatkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965.","journal-title":"Front Immunol"},{"key":"383_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0594-0","volume":"7","author":"HL Kaufman","year":"2019","unstructured":"Kaufman HL, Atkins MB, Subedi P, et al. The promise of immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019;7:129.","journal-title":"J Immunother Cancer"},{"issue":"36","key":"383_CR6","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"2","key":"383_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"2","key":"383_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000515","volume":"27","author":"DA Cobb","year":"2021","unstructured":"Cobb DA, Lee DW. Cytokine release syndrome biology and management. Cancer J. 2021;27(2):119\u201325.","journal-title":"Cancer J."},{"issue":"14","key":"383_CR9","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.3390\/ijms22147652","volume":"22","author":"M Cosenza","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with t-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021;22(14):7652.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"383_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"key":"383_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807050","volume":"13","author":"SH Tay","year":"2022","unstructured":"Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst AM, Chan YH, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol. 2022;13:807050.","journal-title":"Front Immunol"},{"issue":"3","key":"383_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0363","volume":"3","author":"A Haslam","year":"2020","unstructured":"Haslam A, Herrera-Perez D, Gill J, Prasad V. Patient experience captured by quality-of-life measurement in oncology clinical trials. JAMA Netw Open. 2020;3(3):e200363.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"383_CR13","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1111\/jocn.17154","volume":"33","author":"T Watts","year":"2024","unstructured":"Watts T, Roche D, Csontos J. Patients\u2019 experiences of cancer immunotherapy with immune checkpoint inhibitors: a systematic review and thematic synthesis. J Clin Nurs. 2024;33(8):2885\u2013904.","journal-title":"J Clin Nurs"},{"key":"383_CR14","unstructured":"Administration USFaD. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments guidance for industry, Food and Drug Administration staff, and other stakeholders. US FDA; 2022."},{"key":"383_CR15","unstructured":"Administration USFaD. Patient-focused drug development: methods to identify what is important to patients. 2022."},{"key":"383_CR16","unstructured":"Research FoC. Broadening the definition of tolerability in cancer clinical trials to better measure the patient experience. 2018 [cited]; Available from: https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Comparative-Tolerability-Whitepaper_FINAL.pdf#:~:text=Tolerability%20is%20a%20complex%20concept,are%20most%20burdensome%20to%20patients."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00383-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:15:27Z","timestamp":1764087327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00383-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00383-x","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Edward Wells, James Turnbull, and Matthew Reaney are employees of IQVIA, which received funding from Sanofi to conduct this study. Laurence Lucats, Joyce R. Talavera, Sophie R. Van Tomme, Benoit Arnould, Catherine Coulouvrat, and Paul Cordero are employees of Sanofi and may hold stocks or stock options in the company. Giovanni Abbadessa was an employee of Sanofi when this study was conducted and may hold stocks or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki 1964 and its later amendments and is consistent with Good Clinical Practice and applicable regulatory requirements. Centralized approval was obtained from the Western IRB-Copernicus Group (WCG) IRB, including for all recruitment materials. IQVIA is responsible for submitting the application and all study documents for study approval to the IRB. The study was initiated only after IRB approval was granted, including the use of all recruitment materials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained prior to performing any study-related procedures, including screening, and patients provided consent via the online consent form. Patients were informed that, if the results of the study were published for scientific purposes, the patient\u2019s identity would remain confidential. Clinicians who participated in the CD interviews provided verbal consent at the start of the interview after the objectives and logistics of the interview were shared with them. They provided verbal consent to both participate and to also be audio-recorded.A standard ethics approved informed consent process was followed for all patients involved in this study. This required their review and signature of an informed consent form document that clearly outlined the study background, objectives, and procedures (including screening, risks and benefits, compensation, confidentiality, information use and data sharing, and voluntary participation and withdrawal). Completed and signed forms were reviewed by the study team for completeness prior to any interviews being conducted. For participating clinicians, informed consent was obtained verbally at the start of each interview. Prior to providing consent, clinicians were informed of the study background and objectives, interview logistics, and information regarding their confidentiality and how their data will be used.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors would like to thank SparkCures and Rare Patient Voice for their patient advocacy and support during interviews and the patients for their contributions to the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Thanking Patients"}}]}}